📊 KALV Key Takeaways
Is KALV a Good Investment? Thesis Analysis
KalVista demonstrates strong revenue growth (+294% YoY) and maintains exceptional liquidity ($243.5M cash, 7.22x current ratio) with low debt (0.31x leverage), providing a ~2 year cash runway. However, severe operating losses (-$154.7M) with negative free cash flow (-$128.8M) and critically thin equity ($17M) against massive asset base ($339.9M) create substantial execution risk until the company achieves profitability.
Why Buy KALV? Key Strengths
- Exceptional revenue growth of 294% year-over-year demonstrates strong market traction
- Fortress balance sheet with $243.5M cash (71% of total assets) and low debt burden (0.31x debt-to-equity)
- Superior liquidity ratios (7.22x current, 7.21x quick) provide substantial operational flexibility and 2-year burn runway
KALV Investment Risks to Consider
- Severe cash burn of $127M operating cash flow and -$128.8M free cash flow with only $13.7M revenue limits runway without major inflection
- Critically undercapitalized with only $17M stockholders equity against $339.9M liabilities creates vulnerability to adverse events
- Pharmaceutical pre-profitability model carries execution risk; company must demonstrate path to gross margin sustainability and operating leverage
Key Metrics to Watch
- Revenue growth trajectory and gross margin emergence
- Monthly cash burn rate trend relative to revenue acceleration
- Operating cash flow inflection point toward positive territory
KALV Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 7.22x current ratio provides a solid financial cushion.
KALV Profitability Ratios
KALV vs Healthcare Sector
How KalVista Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is KALV Overvalued or Undervalued?
Based on fundamental analysis, KalVista Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
KALV Balance Sheet & Liquidity
KALV 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: KalVista Pharmaceuticals, Inc.'s revenue has declined by 21% over the 5-year period, indicating business contraction. The most recent EPS of $-3.44 indicates the company is currently unprofitable.
KALV Growth Metrics (YoY)
KALV Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.4M | -$40.4M | $-0.87 |
| Q3 2025 | $13.7M | -$25.3M | $-0.84 |
| Q3 2021 | $1.6M | -$5.9M | N/A |
| Q2 2021 | $3.9M | -$5.9M | N/A |
| Q1 2021 | $3.4M | -$7.3M | N/A |
| Q3 2020 | $1.6M | -$3.3M | N/A |
| Q2 2020 | $3.9M | -$3.3M | N/A |
| Q1 2020 | $3.4M | -$5.0M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
KALV Capital Allocation
KALV SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for KalVista Pharmaceuticals, Inc. (CIK: 0001348911)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 27, 2026 | 4 | xslF345X06/form4-03272026_090302.xml | View → |
| Mar 25, 2026 | 8-K | d127514d8k.htm | View → |
| Mar 10, 2026 | 4 | xslF345X05/form4-03102026_100330.xml | View → |
| Feb 24, 2026 | 4 | xslF345X05/form4-02252026_120243.xml | View → |
| Feb 24, 2026 | 4 | xslF345X05/form4-02252026_120256.xml | View → |
❓ Frequently Asked Questions about KALV
What is the AI rating for KALV?
KalVista Pharmaceuticals, Inc. (KALV) has an AI rating of HOLD with 45% confidence, based on fundamental analysis of SEC EDGAR filings.
What are KALV's key strengths?
Claude: Exceptional revenue growth of 294% year-over-year demonstrates strong market traction. Fortress balance sheet with $243.5M cash (71% of total assets) and low debt burden (0.31x debt-to-equity).
What are the risks of investing in KALV?
Claude: Severe cash burn of $127M operating cash flow and -$128.8M free cash flow with only $13.7M revenue limits runway without major inflection. Critically undercapitalized with only $17M stockholders equity against $339.9M liabilities creates vulnerability to adverse events.
What is KALV's revenue and growth?
KalVista Pharmaceuticals, Inc. reported revenue of $13.7M.
Does KALV pay dividends?
KalVista Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find KALV SEC filings?
Official SEC filings for KalVista Pharmaceuticals, Inc. (CIK: 0001348911) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KALV's EPS?
KalVista Pharmaceuticals, Inc. has a diluted EPS of $-2.97.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KALV a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, KalVista Pharmaceuticals, Inc. has a HOLD rating with 45% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KALV stock overvalued or undervalued?
Valuation metrics for KALV: ROE of -934.8% (sector avg: 15%), net margin of -1,160.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KALV stock in 2026?
Our dual AI analysis gives KalVista Pharmaceuticals, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KALV's free cash flow?
KalVista Pharmaceuticals, Inc.'s operating cash flow is $-127.0M, with capital expenditures of $1.9M. FCF margin is -940.5%.
How does KALV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,160.0% (avg: 12%), ROE -934.8% (avg: 15%), current ratio 7.22 (avg: 2).